Why a Deduction Is Worth More Today Than Later

The 2022 U.S. R&D rule changed a timing variable: when a company could begin using its tax deduction. This chapter follows one R&D spending cohort through immediate expensing and through the capitalization-and-amortization schedule studied by Stanford researchers. The goal is to make the economic mechanism precise enough to use later: an expense paid today can become more expensive after tax when the associated relief is postponed, even if the nominal deductions eventually total the same amount.

That distinction matters because R&D is an investment with an unusual cash profile. Researchers, equipment, software, and experiments require funding before a new product or process produces revenue, and the payoff may never arrive. A deduction is one of the few parts of that sequence that can reduce the current cost with some predictability. Moving it into the future changes the amount of cash the firm must carry while it waits for the uncertain payoff.

One R&D cohort, two deduction schedules

Under the immediate-expensing treatment that preceded the studied change, a firm could generally deduct 100% of qualifying R&D costs in the year it incurred them. The deduction reduces taxable income; it is not a cash refund equal to the expense. If a company spends $100 and can use the deduction at a 21% tax rate, the immediate tax benefit is an illustrative $21. The company still paid the $100, but its after-tax cost is lower because the tax saving arrives at once.

The historical capitalization rule kept the cost in the business as an asset for tax purposes and released the deduction over time. In practical terms, the paper describes a five-year amortization period that distributes one spending cohort across six tax years: 10% in year 1, 20% in each of years 2 through 5, and the remaining 10% in year 6.

The table follows one cohort, not the company’s entire R&D program. A firm that spends every year creates overlapping cohorts: while the first year’s spending is being amortized, new spending creates another schedule. That overlap is why the change can be hard to see by looking only at the eventual total. The company has not stopped spending, but the tax relief associated with each new dollar now trails the cash expense.

The Stanford paper uses $410 million as the average annual R&D expenditure in its illustrative calculation. Under immediate expensing and a 21% corporate tax rate, the spending year would produce an $86.1 million tax benefit. Under the new schedule, only 10% of the $410 million—$41 million—would be deductible in the first year, yielding an $8.61 million benefit. The difference is $77.49 million of tax relief not available in that year for this representative cohort.

That difference is not automatically a permanent loss. The remaining deductions are scheduled to arrive. But “not permanently lost” is not the same as “economically neutral.” The company has already paid researchers and suppliers. It may need to borrow, draw down cash, postpone equipment purchases, reduce a payout, or reduce the research program itself while waiting for deductions attached to an earlier expense.

Scaling the example down to a $100 R&D expense makes the cash bridge even clearer. If the firm can use the deduction and faces a 21% rate, immediate expensing lowers the current tax bill by $21, leaving a simplified after-tax cash cost of $79. Under the studied schedule, the first-year deduction is only $10, so the current tax saving is $2.10 and the first-year after-tax cash cost is $97.90. The later benefits are $4.20 in each of the next four years and $2.10 in the sixth year. Their nominal total still equals $21, but the firm has to finance an additional $18.90 of current cost before considering the value of those later benefits. This is a stylized illustration, not a filing calculation; it assumes the firm has taxable income against which the deduction can be used and ignores other tax attributes. It isolates the timing channel.

For a continuing R&D program, the schedules overlap rather than disappear. In year 2, the first cohort contributes a 20% deduction while the second cohort contributes 10%, so the company deducts 30% of one year’s spending in this simplified steady-spending pattern. By year 6, the first cohort contributes its final 10%, four intermediate cohorts contribute 20% each, and the current cohort contributes 10%, bringing the flow to 100% of one year’s spending. The eventual steady flow can make the policy look neutral in a mature tax schedule. It does not erase the transition: the firm had to absorb the shortfall in earlier years, and a fast-growing research program keeps adding new cohorts whose relief is still delayed.

The funding implication is also asymmetric across projects. A company choosing between a research program and a project with a faster cash return may value the immediate deduction differently from a company that can wait. The tax rule does not change the scientific uncertainty of the experiment, but it changes the amount of cash tied up while that uncertainty is being resolved. In that sense, the deduction schedule acts like a financing term attached to R&D: shorter tax recovery reduces the amount of private capital the firm must carry, while longer recovery increases it.

Why the calendar changes the economics

Present value is the bridge between a tax schedule and an investment decision. A dollar received in the future is worth less than a dollar received now when the firm could invest today’s dollar, avoid financing costs, or use it in another project. To compare tax benefits across years, the paper discounts future benefits using an 8% rate in its illustration. A benefit of $1 next year is divided by 1.08; a benefit two years away is divided by 1.08 twice. The precise discount rate is an assumption, but the direction does not depend on choosing 8%: delay reduces present value when time has a positive cost.

For the $410 million annual-spending example, the paper calculates six years of cumulative present-value tax savings under two regimes. With immediate expensing, each year’s $410 million expenditure produces its $86.1 million tax benefit in that same year, for cumulative benefits of $516.6 million over six years. With capitalization and amortization, the benefits from each annual cohort arrive later. By the end of the six-year illustration, their cumulative present value is about $262.6 million—roughly half as large under the assumptions used.

This comparison is not saying that a company receives only $262.6 million of nominal deductions forever. It is comparing the value, at the relevant time, of tax benefits arriving on different schedules. Nor is it a universal forecast. The result depends on the R&D path, the discount rate, the tax rate, and whether the firm can use the deduction. A company with a different tax position or a different pattern of spending will have a different numerical result. The mechanism is the robust part: earlier relief has a higher value than otherwise identical relief that arrives later.

The schedule also raises the after-tax user cost of R&D. Before the change, the firm could treat the tax saving as part of the economics of the current investment. After the change, the first-year cash cost is closer to the pre-tax cost because only a small portion of the deduction offsets current taxes. A manager comparing two projects may therefore see a project with the same technical promise but a higher funding requirement in the period when the project is being built.

This does not mean tax policy mechanically determines whether a project is approved. Innovation has strategic value, adjustment costs, and uncertain payoffs. A company may preserve R&D because abandoning a research program would destroy scarce knowledge or delay a product launch. It may have enough cash to absorb the difference. Or it may shift the burden to a less visible budget line. The timing change creates pressure; it does not dictate one identical response for every firm.

The distinction between a single cohort and a steady R&D stream is especially important. For one cohort, the new schedule clearly postpones most deductions. For a company with constant spending, overlapping schedules eventually create a more even flow of deductions. The paper notes that, under constant R&D spending, annual nominal deductions equalize around year 6. Yet the firm had to finance the transition years with less current relief, and the early shortfall is not recovered in present-value terms. A level stream of later deductions cannot undo the opportunity cost of cash that was unavailable when the projects were launched.

Cash taxes, current tax, and deferred tax are different signals

The tax-timing mechanism becomes confusing when several measures are called “the tax rate.” The Stanford study focuses on cash effective tax rate and current effective tax rate. Cash ETR is cash taxes paid divided by pre-tax income. Current ETR is current tax expense divided by pre-tax income. Both are attempts to measure the tax burden associated with the period, but they do not answer exactly the same question.

Capitalization creates a gap between the tax deduction recognized now and the tax deduction that will be recognized later. That gap can appear as a deferred tax asset: an accounting representation of future tax benefits created by a temporary difference between book and tax treatment. A deferred tax asset is not cash in the bank. It records expected future relief, subject to the applicable accounting and tax conditions. The company can report an asset associated with future deductions while paying more cash tax today.

This is why the policy can sharply increase a cash-based measure without producing an identical movement in a GAAP-based measure. In the paper’s representative calculation, immediate expensing produces a current cash tax saving, while capitalization leaves the total nominal tax treatment spread across future periods. The study’s estimated 11.9-percentage-point increase in cash ETR and 9.9-point increase in current ETR are therefore evidence of a near-term burden, not proof that the company’s lifetime nominal tax bill rose by the same percentage.

The distinction is economically consequential. Cash paid to the government today cannot be used to pay a researcher today, and a future tax asset does not fund payroll unless the firm can bridge the intervening period. The financial statement may show that the tax benefit has not vanished; the treasury department still has to find the cash.

The reverse can also occur. A firm with tax losses, net operating loss carryovers, foreign income, or other tax attributes may not experience the same immediate value from a deduction as a profitable domestic firm. The paper’s numerical example assumes a usable tax benefit and a particular rate. Its empirical analysis controls for several firm characteristics, but the underlying economics remain conditional on tax position and exposure. “A deduction is delayed” is the beginning of the analysis, not the end.

What the mechanism predicts—and what it does not

The mechanism makes a clear prediction about concentration. The larger the exposed R&D base, the larger the current tax relief that is postponed. The tighter the firm’s financing capacity, the more difficult it is to absorb the temporary cash demand. This is why a tax change can have a modest average effect while creating a large effect for particular firms. A cash-rich company may carry the timing difference; a cash-poor company may have to cancel or delay a project.

It also predicts substitution. If R&D is central to a company’s long-term strategy, management may protect it by reducing capital expenditure or share repurchases. That response still has an economic cost: the tax policy has changed the allocation of capital even if the R&D line does not move. Conversely, a constrained firm may be unable to protect every research program and may cut R&D directly.

What the mechanism does not predict by itself is which projects will be cut, whether the cut is temporary, or whether innovation quality will rise or fall. Those questions require evidence beyond the deduction schedule. They depend on project portfolios, managerial priorities, financing alternatives, and the time required for research to produce measurable outcomes.

The strongest conclusion from the timing model is narrower and more useful. Tax relief is part of the financing of an investment. A delayed deduction can leave the nominal tax rules looking broadly similar over a long horizon while changing the cash required in the present. That present requirement is where firm differences become consequential.

A careful reader should therefore carry four labels into any discussion of the policy: nominal versus present value, tax accounting versus cash tax, exposed spending versus total R&D, and historical schedule versus applicable current law. Keeping those labels attached prevents a future deduction from being mistaken for current funding—and prepares the ground for distinguishing the deduction from the separate research credit and its narrower eligibility rules.

References

• The Consequences of Limiting the Tax Deductibility of R&D
• Stanford working paper viewer